



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,369	08/23/2006	Jay A. Nelson	899-73077-04	7108
24197	7590	07/16/2007	EXAMINER	
KLARQUIST SPARKMAN, LLP			WANG, SHENGJUN	
121 SW SALMON STREET				
SUITE 1600			ART UNIT	PAPER NUMBER
PORLTAND, OR 97204			1617	
			MAIL DATE	DELIVERY MODE
			07/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/564,369	NELSON ET AL.	
	Examiner	Art Unit	
	Shengjun Wang	1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 10 April 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,5-19,35-46,80-93 and 103-131 is/are pending in the application.
- 4a) Of the above claim(s) 6-8,35-46,80-84,86-88,90-92 and 103-117 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1,5-9-19,85,89,93 and 118-131 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____.

DETAILED ACTION

Applicants' election of invention group XLVIII drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor. Claims 1, 5, 9-19, 85, 89, 93, 118-131 read on elected invention. In view of the complexity of the elected invention, further restriction within the elected invention is required

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group A, claim(s) 1, 5, 9-10, 85, 89, 93, 118-122 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula I;

Group B, claim(s) 1, 5, 9, 11, 85, 89, 93, 118-121, 123 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula I(b);

Group C, claim(s) 1, 5, 9, 12, 85, 89, 93, 118-121, 124 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula II;

Group D, claim(s) 1, 5, 9, 13-18, 85, 89, 93, 118-121, 125-130 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula III;

Group E, claim(s) 1, 5, 9, 85, 89, 93, 118-121 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula IV;

Group F, claim(s) 1, 5, 9, 19, drawn to 85, 89, 93, 118-121, 131 drawn to a method for the treatment of HIV comprising administering an inhibitor of c-yes kinase, wherein the inhibitor is a small molecular inhibitor, wherein the small molecules are defined by formula V.

2. The inventions listed as Groups A to F do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the compounds employed in groups A to F are structurally distinct compounds, and one of ordinary skill in the art would have reasonably expected that they possess distinct chemical, physical, and biological properties. They therefore lack a core technical feature.

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Various compounds encompassed thereby.

Applicant is required, in reply to this action, to elect a single species (i.e., a single compound) to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

4. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: each of the inventions encompasses compounds with structurally distinct moieties.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SHENGJUN WANG
PRIMARY EXAMINER
Shengjun Wang
Primary Examiner
Art Unit 1617